CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on creating a novel immunotherapy for malignant pleural mesothelioma by using self-amplifying RNA delivered via targeted lipid nanoparticles. The goal is to activate the tumor microenvironment to improve treatment outcomes for this aggressive cancer.
Malignant pleural mesothelioma (MPM) is a highly aggressive disease, where chemotherapy remains the standard of care, enabling an overall survival (OS) of 12 months.
Anti-PD-1-based immunotherapy has not improved the patient's OS, while providing only a response rate of 21%, owing to the immunosuppressive tumor microenvironment.The originality of this proposal relies on engineering a novel form of immunotherapy for the treatment of MPM, through activating the innate and adaptive tumor microenvir…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Portugal, Coimbra
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
